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Introduction Urine is an ideal matrix for metabolomics investigation due to its non-invasive 
nature of collection and its rich metabolite content. Despite the advancements in mass 
spectrometry and 1H-NMR platforms in urine metabolomics, the statistical analysis of the 
generated data is challenged with the need to adjust for the hydration status of the person. 
Normalization to creatinine or osmolality values are the most adopted strategies, however, each 
technique has its challenges that can hinder its wide application.  
Objective Assessment of whether the statistical model established using a targeted urine 
metabolomics dataset for the differential diagnosis of asthma and chronic obstructive pulmonary 
disease (COPD) would be improved by normalization to osmolality instead of creatinine. 
Methods A metabolomics dataset from 51 patient urine samples previously analyzed using two 
liquid chromatography-tandem mass spectrometry methods was used. The data was normalized to 
creatinine and osmolality. The statistical analysis was achieved using partial least square 
discriminant analysis and models of separation were generated and compared.  
Results Creatinine and osmolality values in asthma and COPD patients were strongly correlated. 
Using the same metabolites, we found that normalization to osmolality did not significantly change 
the results. The metabolites of importance in separation remained the same for both methods. The 
statistical strength of the creatinine model was somewhat better than the osmolality normalized 
model (R2Q2=0.919, 0.705 vs R2Q2 =0.929, 0.671).  
Conclusion Our findings suggest that targeted urine metabolomics data can be normalized to 
creatinine or osmolality with no significant impact on the diagnostic accuracy of the model.   
 




1. Introduction  
Metabolomics aims at identifying and quantifying metabolites that are altered in a biological 
system in response to illness or drug therapy (Khamis et al., 2015). Among the various biological 
samples, urine is appealing for metabolomic investigation. It does not demand extensive sample 
preparation steps with its lower protein content, and it is collected non-invasively in large volumes 
(Nobakht M. Gh et al., 2014, Fernández-Peralbo and Luque de Castro, 2012). Urine has been 
widely used in studying cancer (Wu et al., 2009, Issaq et al., 2008), hepatobiliary diseases (Wang 
et al., 2012), psychiatric disorders (Zheng et al., 2010) and respiratory illnesses (Saude et al., 2011, 
Saude et al., 2009, Adamko et al., 2015, Adamko et al., 2012). Using 1H-NMR, Adamko et al. 
(Adamko et al., 2015) has found that the urinary metabolomic profile of asthma patients is different 
from that of chronic obstructive pulmonary disease (COPD) patients. This difference was 
attributed to a set of metabolites identified through partial least square discriminate analysis (PLS-
DA). PLS-DA is a supervised multivariate statistical tool widely used in metabolomics 
(Szymańska et al., 2012). It investigates the relationship between multiple predictor variables 
(metabolomics data) and dependent categorical variables (classes of participants) (Szymańska et 
al., 2012, Wold et al., 2001). If a statistically significant discrimination model can be found 
between classes, PLS-DA then uses the model parameters to predict subjects of unknown origin, 
given their metabolomics data (Szymańska et al., 2012, Wold et al., 2001). 
One important challenge in urine metabolomic analysis is the variation in urine volume, which 
inversely affects metabolite concentration (Ryan et al., 2011, Wu and Li, 2016). Accordingly, prior 
to statistical comparison between participant groups, it is necessary to normalize the data to a 
common denominator to account for the hydration state of the individual (Warrack et al., 2009, 
Ryan et al., 2011). Creatinine (CRNN) has been widely used for normalization since its glomerular 
filtration is relatively constant under normal conditions (Warrack et al., 2009, Slupsky et al., 2007, 
Ryan et al., 2011, Wu and Li, 2016). However, there have been concerns with its validity since its 
excretion can vary with age, gender, race and muscle mass difference (Slupsky et al., 2007, Ryan 
et al., 2011). Osmolality (OSM) values can be also used for normalizing urine data. It is affected 
by the total number of solute particles in urine and can be used to reflect urine concentration (Chen 
et al., 2015, Fernández-Peralbo and Luque de Castro, 2012, Wu and Li, 2016). Unlike CRNN, 
OSM is not affected by age, gender, stress or diet (Warrack et al., 2009, Chen et al., 2015, Wu and 
Li, 2016). The widespread use of OSM is hindered by the absence of the necessary equipment in 
typical laboratories (Chadha et al., 2001, Wu and Li, 2016). In addition, insoluble particles and 
sample heterogeneity can affect the accuracy of the measurements (Chen et al., 2015, Wu and Li, 
2016). While CRNN and OSM are the most widely accepted normalization strategies (Chen et al., 
2015), other strategies have been proposed, such as dansylation and MSTUS (Wu and Li, 2016, 
Wu and Li, 2012). Each technique has its own limitations, as such, there is no universally accepted 
procedure for urine volume normalization. Moreover, comparative studies between all methods of 
normalization are not available (Fernández-Peralbo and Luque de Castro, 2012, Vogl et al., 2016).  
Comparison of normalization techniques using OSM and CRNN was reported in untargeted urine 
metabolomic platforms (Warrack et al., 2009, Chen et al., 2015, Vogl et al., 2016, Chetwynd et 
al., 2016, Kennedy et al., 2016) or with the use of unsupervised multivariate statistical analysis 
such principle component analysis (PCA) (Warrack et al., 2009, Chetwynd et al., 2016). In the 
scarce studies using targeted analysis, only few metabolites were investigated (less than 5) (Reid 
et al., 2012, Barber and Wallis, 1986). In general, results within available literature are conflicting, 
and are confounded with the recruitment of patients with established compromised kidney 
functions. Khamis et al. and Hanan et al. (Khamis et al., 2017, Awad et al., 2016) have developed 
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liquid chromatography (LC)- tandem mass spectrometric (MS/MS) methods for the absolute 
quantification of 32 potential urine biomarkers previously identified by 1H-NMR (Adamko et al., 
2015). Differential isotope labeling was used to provide accurate absolute quantitative data along 
with the use fully validated methods as per regulatory agencies guidelines (Khamis et al., 2017, 
Awad et al., 2016, 2011, 2013). PLS-DA was used for the differentiation of diseases based on 
post-acquisition CRNN normalized metabolite values quantified by LC-MS/MS (Khamis et al., 
2017, Awad et al., 2016). In this work, we hypothesized that the method of post-acquisition urine 
normalization, CRNN or OSM, might have an impact on the metabolomic results. Accordingly, 
we used metabolomic data from asthma and COPD patient urine samples analyzed using 
established methodologies (Khamis et al., 2017, Awad et al., 2016) to compare the accuracy of 
CRNN- and OSM- post acquisition normalized models. In addition, since the ultimate goal is to 
identify a smaller subset of biomarker metabolites, we investigated the effect of urine 
normalization on the biomarkers statistically identified as significant for group separation. This 
work represents the first comparison between CRNN- and OSM- post acquisition normalization 
strategies using a larger set of targeted metabolites (32 in total) that are quantified using differential 
isotope labeling-LC-MS/MS platform.  
2. Experimental 
2.1.Patients characteristics and sample collection 
Fifty-one mid-stream urine samples from consenting patients were collected. Ethics board 
approval has been obtained (Bio#1389) (Khamis et al., 2017, Adamko et al., 2015). Subjects had 
a previous physician based diagnosis of asthma (n=25; female=14; mean age ±SD of 54.1±10.92) 
or COPD (n=26, female=13; mean age ±SD of 60.8± 9.30). 
2.2.Creatinine measurement 
Urinary CRNN concentration was determined using QuantiChrom™ CRNN assay kit (QC, CA) 
(Chen et al., 2015, Kit). The colored complex formed with picric acid in alkaline medium by Jaffe’s 
reaction was detected at 510 nm using BioTek Synergy™ HT Multi-Mode Microplate Reader (VT, 
USA).  
2.3.Osmolality measurement 
Urine samples were vortexed for 10 sec and aliquots of 200 µL were transferred into new sample 
tubes. The OSM was measured using a freezing point depression osmometer (Model 3250, 
Advanced Instruments, MA, USA).  
2.4.Statistical analysis 
The concentrations of 32 metabolites were previously measured using two LC-MS-MS methods 
(Khamis et al., 2017, Awad et al., 2016). Patients’ data was normalized (post acquisition) by 
dividing metabolite concentration (g/L) by CRNN (g/L) or OSM (Osm/Kg) values. Data was then 
exported to SIMCA® software (SIMCA-P 11, Umetrics, Sweden) for PLS-DA. Two statistical 
models of separation were created (32 metabolites/urine sample). Each model is represented by an 
R2 value (multiple correlation coefficient), which explains the data variation, and by a Q2 value 
(cross validated R2), which predicts the data variation (Wold et al., 2001). In the CRNN model, 10 
asthma and 10 COPD patients from CRNN-normalized metabolite values were used as a training 
set, while the remaining CRNN-normalized patients’ data was withheld from modeling in order to 
be run blindly for diagnostic accuracy. In the OSM statistical model, the OSM-normalized dataset 
of the same 10 asthma and 10 COPD patients was used as a training test. Likewise, the remaining 
OSM-normalized patient’s samples were withheld as a test set for accuracy assessment. 
Metabolites with consistently greater differences in concentration between asthma and COPD 
groups are displayed as a Variables of Importance Plot (VIP). The difference in each metabolite 
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for each group of patients is shown as a Coefficient of Variation (COV) plot. PLS-DA generates 
prediction scores based on the separation of data between subject groups. GraphPad Prism 
software (version 6; GraphPad Software, San Diego), was used for the generation of prediction 
score plots. 
3. Results and discussion  
CRNN and OSM values were measured in urine samples of 25 asthma and 26 COPD patients. 
Values of CRNN and OSM were not statistically different between asthma and COPD subjects 
(CRNN p=0.77 or OSM p=0.11; Fig. 1). The correlation of OSM and CRNN in each patient was 
also compared. There was a strong correlation between OSM and CRNN values (Spearman rank 
correlation coefficients (Mukaka, 2012) of 0.9006 and 0.8976 (p<0.001) in asthma and COPD 
patients, respectively) (Fig.2). This agrees with the literature, in which the relationship between 
CRNN and OSM is proportional to kidney functions (Vogl et al., 2016, Reid et al., 2012).   
PLS-DA was performed using 32 metabolites normalized to CRNN or OSM in the asthma and 
COPD subjects and the prediction score plots were generated (Fig.3). The CRNN based PLS-DA 
model could separate asthma from COPD subjects with an R2Y value of 0.919 and a Q2 value of 
0.705. The same subjects from the OSM-normalized dataset were then used for the generation of 
the OSM model, which had an R2Y value of 0.929 and a Q2 value of 0.671. As seen from the 
generated data, the R2 values, which indicate how well the models explain the dataset (Szymańska 
et al., 2012, Wold et al., 2001), are similar between the CRNN and OSM models. These findings 
showed insignificant impact of the normalization approach on the statistical quality of the PLS-
DA generated models. Similarly, Q2 values also suggest the minimal difference in the predictive 
power between the CRNN based- and OSM based- PLS-DA models.  
In addition, the effect of normalization between disease groups for each of the 32 metabolites was 
assessed. The method of urine normalization had no significant impact on the coefficient of 
variation values, being positive (COPD) or negative (Asthma) (Fig. 4). With the exception of one 
metabolite (tryptophan), all metabolites consistently increased or decreased between diseases 
regardless of the method of normalization (Fig.4). The marginal exception of tryptophan (Fig.4) 
is attributed to its larger than average variation between subjects and wide error bars. In addition, 
tryptophan variation was not a concern for the intended purpose as this amino acid was not a key 
metabolite used in disease separation based on the VIP plot of each model (data not shown).  
The metabolites used in the model are ranked and displayed as a VIP. Metabolites with a VIP score 
>1 are more important to the strength of separation, and removing these metabolites will weaken 
a model. We investigated if the method of normalization might have an impact on the metabolites 
chosen as important in each PLS-DA model. Twelve metabolites had a VIP score>1 in CRNN 
model, while 11 metabolites had a VIP score>1 in OSM model. All but one metabolite were similar 
between the two models (data not shown). Accordingly, it can be conferred that CRNN or OSM 
normalization has no significant effect on the metabolites identified as significant between patient 
groups.  
The last aim was to compare the predictive ability of each normalization technique for blinded 
sample analysis. CRNN- or OSM- normalized data of 15 asthma and 16 COPD patients were 
shown to the respective PLS-DA models without a diagnosis. The model generates a prediction 
score for the disease category in which the samples best fit. For the CRNN normalized dataset, the 
model was able to correctly diagnose 14 out of 15 (93% accuracy) asthma patients and 15 out of 
16 COPD patients (93% accuracy). Similarly, when the OSM-normalized PLS-DA model was 
used to predict the diagnosis of the same blinded patient set using their OSM-normalized urine 
metabolomics data, the model demonstrated an accuracy of 87% (n=13 out of 15) and 75% (n =12 
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out of 16). Both models were reasonably good given the small sample size and thus the larger 
weight imposed by each participant on the overall accuracy %. The marginally improved 
prediction accuracy of the CRNN model might be explained by the stronger Q2 value.  
Similar to Kennedy et al. (Kennedy et al., 2016), we have demonstrated a consistency in 
biomarkers regardless of CRNN or OSM normalization. Our results are different than Vogl et 
al.(Vogl et al., 2016) or Warrack et al. (Warrack et al., 2009). Vogl et al.(Vogl et al., 2016) 
reported that OSM normalization resulted in the higher percentage of significant features in an 
untargeted urine metabolomics platform. It is important to note that the patient cohort had 
established chronic kidney disease, which would greatly affect creatinine measurements  (Vogl et 
al., 2016). Warrack et al. (Warrack et al., 2009) used rats treated with doses of a lung/liver toxicant 
before PCA analysis, however, their kidney functions were not assessed prior to sample collection.  
4. Conclusion  
Overall, CRNN and OSM post acquisition normalized values were similar between asthma and 
COPD patients. The statistical parameters of the PLS-DA models did not differ significantly 
between the normalization strategies. As such, we suggest that either normalization strategy could 
be used for targeted urine metabolomics using differential isotope labeling if kidney disease is not 
a significant co-morbidity in the subject cohort.  
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